Feed RXRX
RX

Recursion Pharmaceuticals

RXRX · NASDAQ

$4.78 +16.02% (+$0.66)
1M +19.77%
Market Cap $2.51B
P/E Ratio -
Div. Yield -
ROE 50.41%
Analysis

An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.

Piotroski F-Score Weak
3/9
Valuation
36 /100
Fair
P/S 45.72x
P/B 2.74x
P/E N/A
Growth
100 /100
Growing
Rev. growth 23.46%
Book val. growth 32.53%
EPS growth N/A
Profitability
0 /100
Weak
Gross margin 46.66%
FCF margin 645.82%
Net margin 945.92%
Quality
1 /100
Poor
ROIC 48.34%
Asset turnover 0.05x
ROE 50.41%
Debt
69 /100
Low
Debt/Equity 0.07x
Int. coverage -350.41x
Current ratio 5.03x
Stability
75 /100
Stable
Beta 1.07x
Profitable years 0
Rev. volatility 12.06%

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about RXRX
Online

About the company

Recursion Pharmaceuticals is a biotechnology company that utilizes modern technologies such as artificial intelligence and machine learning to discover new therapeutic compounds and potential treatment approaches.

The key element of their approach is the use of image processing and data analysis systems to create comprehensive maps of cellular processes. This aims to identify potential targets for drugs and therapeutic substances in the fields of genetics, cellular biology, and diseases.

Sector

Healthcare

Industry

Biotechnology

CEO

Najat Khan

Employees

600

Headquarters

Salt Lake City

Upcoming events

04 NOV

Earnings

Upcoming earnings report

29d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.